N. Palanisamy

This study identifies adenosine deaminase (ADA) as a driver of prostate cancer progression and metastasis through metabolomics and in vitro/in vivo experiments.

The paper identifies KIT as a therapeutic target for SPINK1-positive prostate cancer through integrative proteomics and shows KIT inhibition reduces tumor growth and metastasis.

This study identifies DKC1 as a key regulator in colorectal cancer progression through WNT signaling, showing its role in sphingolipid biosynthesis and proposing ceramides as potential biomarkers.

This paper introduces BLADE, a blue light-inducible AraC variant in E. coli that enables reversible control of gene expression and morphology, and uses it to study gene function and create bacteriographs.

The paper identifies a transcriptional network involving ERG, AR, and DLX1 in prostate cancer progression and shows BET inhibitors can target this network.

This study shows that C-terminal eYFP fusion to MinE impairs its function in Escherichia coli, affecting its ability to displace MinC, stimulate MinD ATPase activity, and bind to the membrane.

The paper evaluates molecular heterogeneity in prostate cancer biopsy samples using dual immunohistochemistry and RNA in situ hybridization, finding clonal differences and higher heterogeneity in African American patients.

This study identifies PAK4 amplification and overexpression in bladder cancer and shows PAK4 inhibition reduces tumor growth, with potential for combination therapy.

The paper identifies and validates a novel gene fusion in prostate cancer involving KLK4 and KLKP1, showing its association with high Gleason grade tumors and potential as a biomarker.

This study shows that androgen deprivation therapy upregulates SPINK1, which enhances cellular plasticity and contributes to poor outcomes in prostate cancer.

This study identifies miRNA-338-5p and miRNA-421 as epigenetically silenced in SPINK1-positive prostate cancer, and shows their restoration inhibits oncogenic properties.